People in the News
OraSure Technologies has appointed Carrie Eglinton Manner to the role of president and CEO, replacing interim CEO Nancy Gagliano, according to a filing with US Securities and Exchange Commission. Prior to joining OraSure, Eglinton Manner served as senior VP, advanced and general diagnostic and clinical solutions at Quest Diagnostics since January 2017. Prior to Quest, she served in various leadership roles at GE Healthcare, including as president and CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services, and medical devices.
In connection with Eglinton Manner's appointment, Gagliano will resign from her position on June 4.
In addition, Kathleen Weber, OraSure's president of molecular solutions, has also informed the company that she will resign. Pursuant to the terms of her employment, her resignation is planned for Aug. 21, 2022.
StageZero Life Sciences said that Matthew Pietras has resigned as CFO and COO but will support the company as it searches for a new CFO. No reason was given for his resignation. According to his LinkedIn bio, Pietras joined StageZero in August 2021. Prior to that, he was VP of Finance at CiVi Biopharma. Before that, he was controller and treasurer at Viela Bio.
Everett Cunningham has been appointed to the board of directors of infectious disease diagnostics firm Visby Medical. He is the chief commercial officer of Exact Sciences. Previously, he was president and CEO of GE Healthcare's US and Canada region, as well as senior VP of commercial at Quest Diagnostics.
Abdel Halim has joined diagnostics firm Acutis as CSO and executive VP for biopharma and diagnostics services. He will help the Hicksville, New York-baesd company to advance its clinical product development as well as its cancer genomics and biopharma services.
Leslie Teso-Lichtman has joined the board of Chembio Diagnostics. She is SVP and CFO of medical device company CereVasc. Before that, Teso-lichtman was SVP of finance and treasurer of Roche Diagnostics Hematology after it acquired Constitutional Medical Investors, where she was previously employed.
Natera appointed Minetta Liu as its new chief medical officer of oncology, tasked with proving Signatera's clinical utility and incorporating it into standard practice. Liu previously served as professor of oncology and chair of research at the Mayo Clinic in Rochester, NY, where she also co-led the Genomics in Action Strategic Priority for the Center of Individualized Medicine. Additionally, Liu has chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology and has co-chaired the Correlative Science Working Group of the Translational Breast Cancer Research Consortium.
Gradientech has appointed Peter Karlberg as its VP of sales and Urban Adolfsson as its CFO. Hans Richter has ended his assignment as interim CFO, and Elisabet Nielsen is now a new member of Gradientech's scientific advisory board.
Biosensor-based diagnostic company Glympse has appointed Jonathan Wilde as the firm's CSO. Wilde was previously VP of research and collaborations at Veracyte and worked in biomarker discovery and diagnostic development across multiple disease areas at pharmaceutical firms AstraZeneca and GlaxoSmithKline. Wilde has also worked as a consultant for companies like Owlstone Medical and Cytox.
Prostate screening test startup LynxDx said Steve Riggs has become president of the company. Additionally, Spencer Heaton has been named chief medical and commercial officer, and Jeff Crays has been named chief technology officer. In addition to being president of LynxDx, Riggs is the CEO of the Ann Arbor, Michigan-based company. Heaton, meanwhile, is a physician executive experienced in healthcare delivery, healthcare technology services, venture capital, and diagnostics development. Crays has 20 years of experience in emerging technology and business strategy. LynxDx was launched in 2020 and has developed the MyProstateScore, a noninvasive, urine-based test that detects the presence of two genetic biomarkers linked to prostate cancer.
NeoGenomics announced that it has appointed Lynn Tetrault as interim CEO and chair of the board of directors. Tetrault has been executive chair and principal executive officer of the company since March, when former CEO Mark Mallon stepped down, and has been overseeing the interim office of the CEO while NeoGenomics searches for a permanent CEO.
Tetrault has been a board member since 2015, was the lead independent director from 2020 to 2021, and was appointed nonexecutive chair in 2021. She previously served in a variety of roles at AstraZeneca, including EVP of human resources and corporate affairs. She is also a nonexecutive director of Rhythm Pharmaceuticals.
NeoGenomics also announced that Douglas Brown, its chief strategy and corporate development officer, will be leaving the firm on May 27.